Objective  To systematically review the manage effects of prescription refill in hypertension management in our country, and to provide suggestions for chronic disease policies.

Methods  Web of Science, PubMed, Embase, Cochrane Library, SinoMed, CNKI, WanFang Data, VIP databases were electronically searched to collect randomized controlled trails (RCTs) of prescription refill services for hypertension management from inception to March 31, 2024. Two reviewers independently screened the literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was conducted by using RevMan 5.3 software.

Results  A total of 14 RCTs involving 1,386 patients were included. Meta-analysis results showed that systolic blood pressure [MD=- 9.19, 95%CI (-12.20, -6.17), P<0.001], diastolic blood pressure [MD=-4.98, 95%CI (-6.71, -3.26), P<0.001] in experimental group was significantly lower than the control group. Patient compliance score[SMD=2.05, 95%CI (0.44, 3.66), P=0.01], compliance rate[RR=1.15, 95%CI (1.08, 1.23), P<0.001], patient satisfaction[RR=1.28, 95%CI (1.16, 1.42), P<0.001] in experimental group were significantly higher than the control group.

Conclusion  The prescription refill for chronic diseases is rapidly developing in our country, and has achieved remarkable results in the management of hypertension patients. In the future, it is necessary to further promote the safe, effective and standardized implementation of prescription refill services, and carry out high-quality service models with multi-disciplinary participation.

1.国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7): 625-660. [National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2023: an updated summary[J]. Chinese Circulation Journal, 2024, 39(7): 625-660.] DOI: 10.3969/j.issn.1000-3614. 2024.07.001.

2.中国高血压防治指南修订委员会, 中国高血压联盟, 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南（2024年修订版）[J]. 中华高血压杂志（中英文）, 2024, 32(7): 603-700. DOI: 10.16439/j.issn.1673-7245.2024. 07.002.

3.马健. 基于史密斯模型的慢性病长处方政策执行问题及管理对策研究[D]. 太原: 山西医科大学, 2019.

4.国务院办公厅. 国务院办公厅关于推进分级诊疗制度建设的指导意见[EB/OL]. (2015-09-11) [2024-04-16]. https://www.gov.cn/gongbao/content/2015/content_2937321.htm.

5.国家医保局办公室, 国家卫生健康委办公厅. 关于印发长期处方管理规范（试行）的通知[EB/OL]. (2021-08-12) [2024-08-11]. https://www.gov.cn/zhengce/zhengceku/2021-08/13/content_5631140.htm.

6.管雪帆, 贾梦, 王芳, 等. 全国基层医疗卫生机构长期处方政策实施情况调查与分析[J]. 中国社会医学杂志, 2025, 42(1): 1-5. [Guan XF, Jia M, Wang F, et al. Study and analysis of the implementation of the long-term prescription policy in primary health care institutions in China[J]. Chinese Journal of Social Medicine, 2025, 42(1): 1-5.] DOI: 10.3969/j.issn.1673-5625. 2025.01.001.

7.冉红军, 高文娟, 吴浩, 等. 社区卫生服务中心高血压患者对长处方政策实施的看法及相关影响因素研究[J]. 临床药物治疗杂志, 2019, 17(5): 67-72. [Ran HJ, Gao WJ, Wu H, et al. Agreement on refilled prescription policy and its influencing factors in patients diagnosed with hypertension in health service center[J]. Clinical Medicine Journal, 2019, 17(5): 67-72.] DOI: 10.3969/j.issn.1672-3384.2019.05.015.

8.北京市卫生健康委员会. 关于印发北京市8类慢性病长期处方用药指南（2024试行版）的通知[EB/OL]. (2024-09-10) [2024-09-23]. https://wjw.beijing.gov.cn/zwgk_20040/qt/202409/t20240919_3894952.html.

9.刘利勤, 李青. 非洛地平对比硝苯地平治疗中国人原发性高血压的Meta分析及其GRADE证据质量评价[J]. 药物流行病学杂志, 2017, 26(6): 369-374. [Liu LQ, Li Q. Felodipine vs. nifedipine for Chinese patients with essential hypertension:a Meta-analysis and quality of evidence evaluation based on GRADE system[J]. Chinese Journal of Pharmacoepidemiology, 2017, 26(6): 369-374.] DOI: 10.19960/j.cnki.issn1005-0698.2017.06.001.

10.秦英辉. 慢性病长处方签约服务对高血压患者的影响[J]. 中国民康医学, 2022, 34(18): 135-137. [Qin YH. Effects of chronic disease long-term prescription contracted service on hypertensive patients[J]. Medical Journal of Chinese People's Health, 2022, 34(18): 135-137.] DOI: 10.3969/j.issn.1672-0369.2022.18.041.

11.钱伟峰, 徐振中, 赵洁. 社区医院开展慢病长处方治疗高血压患者的临床效果分析[J]. 中国社区医师, 2016, 32(24): 18-19. [Qian WF, Xu ZZ, Zhao J. Clinical effect analysis of chronic diseases long prescription in the treatment of patients with hypertension in community hospital[J]. Chinese Community Doctors, 2016, 32(24): 18-19.] DOI: 10.3969/j.issn.1007-614x.2016.24.7.

12.江燕文. 高血压长处方联合医院-社区综合管理治疗高血压的分析[J]. 心血管病防治知识, 2022, 12(25): 34-36. [Jiang YW. Analysis of hypertension long prescription combined hospital-community comprehensive management for the treatment of hypertension[J]. Prevention and Treatment of Cardiovascular, 2022, 12(25): 34-36.] DOI: 10.3969/j.issn.1672-3015(x).2022. 25.010.

13.翟小繁. 高血压长处方联合医院-社区综合管理模式在治疗高血压患者中的应用效果及安全性分析[J]. 心血管病防治知识, 2020, 10(36): 43-45. [Zhai XF.Application effect and safety analysis of the comprehensive management mode of hypertension long prescription combined hospital in the treatment of hypertension patients[J]. Prevention and Treatment of Cardiovascular, 2020, 10(36): 43-45.] DOI: 10.3969/j.issn.1672-3015(x).2020.36.014.

14.Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised  trials[J]. BMJ, 2011, 343: d5928. DOI: 10.1136/bmj.d5928.

15.邢颖, 逄瑜, 詹思延, 等. 双唾液酸神经节苷脂靶向疗法治疗儿童神经母细胞瘤安全性的系统评价和Meta分析[J]. 药物流行病学杂志, 2025, 34(2): 191-204. [Xing Y, Pang Y, Zhan SY, et al. Safety of disialoganglioside targeted therapies in the treatment of pediatric neuroblastoma:a systematic review and Meta-analysis[J]. Chinese Journal of Pharmacoepidemiology, 2025, 34(2): 191-204.] DOI: 10.12173/j.issn.1005-0698. 202408029.

16.俞恬, 刘少华, 魏安华, 等. 胰高血糖素样肽1受体激动剂治疗合并超重或肥胖的2型糖尿病的疗效和安全性的Meta分析[J]. 药物流行病学杂志, 2024, 33(5): 519-538. [Yu T, Liu SH, Wei AH, et al. Efficacy and safety of glucagon-like peptide 1 receptor agonists in the treatment of overweight or obese patients with type 2 diabetes: a Meta-analysis[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(5): 519-538.] DOI: 10.12173/j.issn.1005-0698.202306027.

17.俞建. 社区医院开展慢病长处方治疗高血压患者的临床效果分析[J]. 养生保健指南, 2018, (13): 100. [Yu J. Analysis of the clinical effect of chronic disease prescription for hypertensive patients in community hospitals[J]. Health Guide, 2018, (13): 100.] DOI: 10.3969/j.issn.1006-6845.2018.13.079.

18.张彬. 社区中心开展慢病长处方治疗高血压患者的临床效果分析[J]. 人人健康, 2018 (16): 78. [Zhang B. Analysis of the clinical effect of chronic disease prescription in the community center[J]. Health for Everyone, 2018(16): 78.] https://kns.cnki.net/kcms2/article/abstract?v=En0qcdJbrGlhYxDT7WhxmG793xjmViuFkp-QOA27ly_20_39zlcEdqccHadgaHlBrHi97vD73MKOIQ7r-tr4HP-WFPzdJJXSN0q9_1ZzljRlx5A8th3dCVOJG3o_Pmow8Vor04kOUVN31eNC4abgpGYnncBD5RxOHq3YVNv8WYZSgD8hdKNUMQ==&uniplatform=NZKPT&language=CHS.

19.谢国良. 社区中心开展慢病长处方治疗高血压患者的临床效果分析[J]. 科学养生, 2021, 24(1): 181. [Xie GL. Analysis of the clinical effect of chronic disease prescription in the community center[J]. Regimen, 2021, 24(1): 181.] https://d.wanfangdata.com.cn/periodical/CiNQZXJpb2RpY2FsQ0hJMjAyNTA1MjIyMDI1MDUyNzE3MTU0NhINa3h5czIwMjEwMTE3NBoIeXdoNjhtbDg%3D.

20.郑东鹏, 卢爱敏, 许友贤, 等. 基于高血压病诊疗实践的上海市慢性病长处方签约服务的效果评价[J]. 中华全科医学, 2019, 17(4): 583-585, 681. [Zheng DP, Lu AM, Xu YX, et al. The evaluation of routine hypertension therapy based contract service on the long-term prescription in Shanghai[J]. Chinese Journal of General Practice, 2019, 17(4): 583-585, 681.] DOI: 10.16766/j.cnki.issn.1674-4152.000741.

21.王勇. 慢病长处方对社区高血压患者管理策略探讨[J]. 中国社区医师, 2020, 36(27): 183-184. [Wang Y. Discussion on the management strategy of long prescription for chronic disease on patients with hypertension in community[J]. Chinese Community Doctors, 2020, 36(27): 183-184.] DOI: 10.3969/j.issn.1007-614x.2020.27.089.

22.徐勇, 周琴, 皋凌子, 等. 慢病长处方对社区高血压患者管理的影响分析[J]. 实用预防医学, 2019, 26(10): 1251-1252. [Xu Y, Zhou Q, Gao LZ, et al. Analysis of the effect of chronic disease long prescription on the management of community hypertensive patients[J]. Practical Preventive Medicine, 2019, 26(10): 1251-1252.] DOI: 10.3969/j.issn.1006-3110.2019.10.026.

23.高建雄, 林淑芳, 翟小繁. 医院-社区联合开展慢病长处方治疗高血压患者的应用研究[J]. 北方药学, 2021, 18(11): 159-161. [Gao JX, Lin SF, Zhai XF. Hospital-community joint research on the application of chronic disease prescription in the treatment of hypertension patients[J]. Northern Pharmacy, 2021, 18(11): 159-161.] DOI: 10.3969/j.issn.1672-8351.2021.11.052.

24.朱化儒. 慢病长处方对社区高血压患者管理的影响分析[J]. 中国卫生产业, 2020, 17(21): 49-51. [Zhu HR. Analysis of the impact of chronic disease long prescription on the management of hypertension patients in the community[J]. China Health Industry, 2020, 17(21): 49-51.] DOI: 10.16659/j.cnki.1672-5654. 2020.21.049.

25.郁梅筠. 高血压治疗中高血压长处方联合医院、社区综合管理方案的作用[J]. 中文科技期刊数据库（文摘版）医药卫生, 2023(6): 15-17. [Yu MY. The role of long prescription hypertension treatment combined with hospital and community comprehensive management in the treatment of hypertension[J]. Chinese Science and Technology Journal Database (Abstract Edition) Medicine and Health, 2023(6): 15-17.] https://old.cqvip.com/QK/71997X/202306/1000003753043.html.

26.翟小繁. 慢病长处方对社区高血压患者用药安全性的影响 [J]. 北方药学, 2021, 18(4): 111-112. [Zhai XF. Effect of chronic disease long prescription on medication safety in community hypertension patients[J]. Journal of North Pharmacy, 2021, 18(4): 111-112.] DOI: 10.3969/j.issn.1672-8351.2021.04.057.

27.Fu R, Xu H, Lai Y, et al. A VOSviewer-based bibliometric analysis of prescription refills[J]. Front Med (Lausanne), 2022, 9: 856420. DOI: 10.3389/fmed.2022.856420.

28.马健, 郑建中, 傅鸿鹏, 等. 国内外长处方服务对比研究[J]. 卫生经济研究, 2019, 36(4): 52-54. [Ma J, Zheng JZ, Fu HP, et al. Comparative study on long-term prescription services at home and abroad[J]. Health Economics Research, 2019, 36(4): 52-54.] DOI: 10.14055/j.cnki.33-1056/f.2019.04.016.

29.朱珠, 尚楠, 范倩倩, 等. 慢性病长期用药处方开展情况的英文文献分析[J]. 中国药师, 2018, 21(1): 136-141. [Zhu Z, Shang N, Fan QQ, et al. Analysis on English literature of prescription refills for chronic diseases[J]. China Pharmacist, 2018, 21(1): 136-141.] DOI: 10.3969/j.issn.1008-049X.2018.01.036.

30.刘洋, 刘鑫, 李亚利, 等. 北京市社区高血压长处方患者慢病管理的药学服务模式评价[J]. 临床药物治疗杂志, 2018, 16(10): 78-80, 89. [Liu Y, Liu X, Li YL, et al. Effectiveness of chronic disease management of hypertension patients with long-term prescriptions in one community in Beijing[J]. Clinical Medication Journal, 2018, 16(10): 78-80, 89.] DOI: 10.3969/j.issn.1672-3384.2018.10.018.

31.刘士勇, 郗海香. 基于高血压病诊疗实践的慢性病长处方签约服务的效果[J]. 慢性病学杂志, 2021, 22(7): 1058-1060. [Liu SY, Xi HX. Effect of long prescription contract service for chronic diseases based on diagnosis and treatment practice of hypertension[J]. Chronic Pathematology Journal, 2021, 22(7): 1058-1060.] DOI: 10.16440/J.CNKI.1674-8166.2021.07.24.

32.翁立立, 陆萍, 沈宏祥, 等. 推广长处方对慢性病患者社区就诊意愿的影响分析[J]. 上海医药, 2017, 38(24): 12-14. [Weng LL, Lu P, Shen HX, et al. Analysis of influence of the extended prescription on the willingness of community visits of the patients with chronic diseases[J]. Shanghai Medical & Pharmaceutical Journal, 2017, 38(24): 12-14.] DOI: 10.3969/j.issn.1006-1533.2017.24.004.

33.高文娟, 陈碧华, 赵立宇, 等. 社区“三色阶梯”长处方管理模式的探索与效果研究[J]. 中国全科医学, 2016, 19(7): 757-761. [Gao WJ, Chen BH, Zhao LY, et al. Exploration  and effect of "tricolor ladder" long-prescription management mode in community[J]. Chinese General Practice, 2016, 19(7): 757-761.] DOI: 10.3969/j.issn.1007-9572.2016.07.004.

34.林其意, 易春涛, 黄涛, 等. 慢性病长处方政策对居民就诊费用及行为的影响[J]. 卫生经济研究, 2018, (2): 57-60. [Lin QY, Yi CT, Huang T, et al. The effect of long prescription policy of chronic diseases on the medical cost and behavior of residents[J]. Health Economics Research, 2018, (2): 57-60.] DOI: 10.14055/j.cnki.33-1056/f.20180206.005.